Evidence map›Paper›PMID 30921693›Full record

ArticleEuropean journal of medicinal chemistry2019

Neutral sphingomyelinase 2 inhibitors based on the 4-(1H-imidazol-2-yl)-2,6-dialkoxyphenol scaffold.

Ondrej Stepanek, Niyada Hin, Ajit G Thomas, Ranjeet P Dash, Jesse Alt, Rana Rais, Camilo Rojas, Barbara S Slusher, Takashi Tsukamoto

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of medicinal chemistry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Extracellular vesicle interplay in cardiovascular pathophysiology.American journal of physiology. Heart and circulatory physiology · 2021
    Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ondrej StepanekJohns Hopkins Drug Discovery, Johns Hopkins University, Baltimore, MD, 21205, USA.
Niyada HinJohns Hopkins Drug Discovery, Johns Hopkins University, Baltimore, MD, 21205, USA.
Ajit G ThomasJohns Hopkins Drug Discovery, Johns Hopkins University, Baltimore, MD, 21205, USA.
Ranjeet P DashJohns Hopkins Drug Discovery, Johns Hopkins University, Baltimore, MD, 21205, USA; Department of Neurology, Johns Hopkins University, Baltimore, MD, 21205, USA.
Jesse AltJohns Hopkins Drug Discovery, Johns Hopkins University, Baltimore, MD, 21205, USA.
Rana RaisJohns Hopkins Drug Discovery, Johns Hopkins University, Baltimore, MD, 21205, USA; Department of Neurology, Johns Hopkins University, Baltimore, MD, 21205, USA.
Camilo RojasJohns Hopkins Drug Discovery, Johns Hopkins University, Baltimore, MD, 21205, USA; Department of Molecular and Comparative Pathobiology, Johns Hopkins University, Baltimore, MD, 21205, USA.
Barbara S SlusherJohns Hopkins Drug Discovery, Johns Hopkins University, Baltimore, MD, 21205, USA; Department of Neurology, Johns Hopkins University, Baltimore, MD, 21205, USA.
Takashi TsukamotoJohns Hopkins Drug Discovery, Johns Hopkins University, Baltimore, MD, 21205, USA; Department of Neurology, Johns Hopkins University, Baltimore, MD, 21205, USA. Electronic address: ttsukamoto@jhmi.edu.

Funding

Therapeutic CoreP30MH075673 · NIMH · JOHNS HOPKINS UNIVERSITY · PI Barbara Stauch Slusher · 2006 to 2026
$33.2M
Regulation of Exosome Secretion as a novel therapeutic approach for Alzheimer's DiseaseR01AG059799 · NIA · JOHNS HOPKINS UNIVERSITY · PI SLUSHER, BARBARA STAUCH, TSUKAMOTO, TAKASHI · 2018 to 2022
$2.4M
High throughput screening (HTS) to discover chemical probes for neutral sphingomyelinase2R01MH107659 · NIMH · JOHNS HOPKINS UNIVERSITY · PI ROJAS, CAMILO · 2015 to 2017
$1.1M
NIA NIH HHS R01 AG059799NIMH NIH HHS P30 MH075673NIMH NIH HHS R01 MH107659
6 · The paper itself

Abstract

Neutral sphingomyelinase 2 (nSMase2), a key enzyme in ceramide biosynthesis, is a new therapeutic target for the treatment of neurological disorders and cancer. Using 2,6-dimethoxy-4-[4-phenyl-5-(2-thienyl)-1H-imidazol-2-yl]phenol (DPTIP), our initial hit compound (IC

Indexed as

AnimalsEnzyme InhibitorsHumansImidazolesMaleMiceMicrosomes, LiverPhenolsSphingomyelin PhosphodiesteraseEnzyme InhibitorsimidazoleImidazolesPhenolsSMPD3 protein, humanSphingomyelin PhosphodiesteraseCeramideGlucuronidationNeutral sphingomyelinase 2PhosphodiesteraseSphingomyelin

Identifiers

PMID30921693
PMCPMC9850959

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.